Pharmacists in France are now allowed to substitute a biosimilar for a prescribed biologic as long as the prescribing physician has not marked the prescription as “non-substitutable.” A law concerning France’s Social Security budget, which came into effect on January 1, has provisions that allow the substitution. [See IPQ August 7, 2012 for an analysis of global regulatory pathways for biosimilars.]
[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
